{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:57:01Z","timestamp":1780466221168,"version":"3.54.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008081","name":"Southeast University","doi-asserted-by":"crossref","award":["Southeast University"],"award-info":[{"award-number":["Southeast University"]}],"id":[{"id":"10.13039\/501100008081","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00280-024-04700-5","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T10:04:50Z","timestamp":1721124290000},"page":"507-516","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of ALDH1A1 and NQO1 gene polymorphisms on the response and toxicity of chemotherapy in Bangladeshi breast cancer patients"],"prefix":"10.1007","volume":"94","author":[{"given":"Md. Siddiqul","family":"Islam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdowsi","family":"Akter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Mosiqur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Rajdoula","family":"Rafe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Abdul","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Parvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abu Syed Md.","family":"Mosaddek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4924-5319","authenticated-orcid":false,"given":"Mohammad Safiqul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Wahid","family":"Akter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"key":"4700_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s43042-022-00240-w","volume":"23","author":"MA Aziz","year":"2022","unstructured":"Aziz MA, Akter T, Sarwar MS, Islam MS (2022) The first combined meta-analytic approach for elucidating the relationship of circulating resistin levels and RETN gene polymorphisms with colorectal and breast cancer. Egypt J Med Hum Genet 23:27. https:\/\/doi.org\/10.1186\/s43042-022-00240-w","journal-title":"Egypt J Med Hum Genet"},{"key":"4700_CR2","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2217\/fon.12.61","volume":"8","author":"JR Benson","year":"2012","unstructured":"Benson JR, Jatoi I (2012) The global breast cancer burden. Future Oncol 8:697\u2013702. https:\/\/doi.org\/10.2217\/fon.12.61","journal-title":"Future Oncol"},{"key":"4700_CR3","unstructured":"WHO (2021) Breast cancer. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer [Accessed: December 21, 2021]"},{"key":"4700_CR4","unstructured":"Bangladesh (2021) The International Agency for Research on Cancer. THE GLOBAL CANCER OBSERVATORY 1\u20132. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/50-bangladesh-fact-sheets.pdf [Accessed 21 May 2022]"},{"key":"4700_CR5","unstructured":"Anadolu Agency (2021) Central database, mass awareness to address breast cancer in Bangladesh. https:\/\/www.aa.com.tr\/en\/asia-pacific\/central-database-mass-awareness-to-address-breast-cancer-in-bangladesh\/2401288 [Accessed 21 May 2022]"},{"key":"4700_CR6","doi-asserted-by":"publisher","first-page":"108391","DOI":"10.1016\/j.mrrev.2021.108391","volume":"788","author":"Y Cura","year":"2021","unstructured":"Cura Y, Ram\u00edrez CP, Mart\u00edn AS et al (2021) Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: clinical relevance and future perspectives. Rev Mutat Res 788:108391. https:\/\/doi.org\/10.1016\/j.mrrev.2021.108391","journal-title":"Rev Mutat Res"},{"key":"4700_CR7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.cpet.2018.02.006","volume":"13","author":"TA Moo","year":"2018","unstructured":"Moo TA, Sanford R, Dang C, Morrow M (2018) Overview of breast Cancer therapy. PET clin 13:339\u2013354. https:\/\/doi.org\/10.1016\/j.cpet.2018.02.006","journal-title":"PET clin"},{"key":"4700_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40364-020-00213-4","volume":"8","author":"NN Miteva-Marcheva","year":"2020","unstructured":"Miteva-Marcheva NN, Ivanov HY, Dimitrov DK, Stoyanova VK (2020) Application of pharmacogenetics in oncology. Biomark Res 8:32. https:\/\/doi.org\/10.1186\/s40364-020-00213-4","journal-title":"Biomark Res"},{"key":"4700_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/sj.tpj.6500242","volume":"4","author":"V Stearns","year":"2004","unstructured":"Stearns V, Davidson NE, Flockhart DA (2004) Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J 4:143\u2013153. https:\/\/doi.org\/10.1038\/sj.tpj.6500242","journal-title":"Pharmacogenomics J"},{"key":"4700_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/nejmra020021","volume":"348","author":"R Weinshilboum","year":"2003","unstructured":"Weinshilboum R (2003) Inheritance and drug response. NEJM 348:529\u2013537. https:\/\/doi.org\/10.1056\/nejmra020021","journal-title":"NEJM"},{"key":"4700_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejphar.2009.08.045","volume":"625","author":"E Wiechec","year":"2009","unstructured":"Wiechec E, Hansen LL (2009) The effect of genetic variability on drug response in conventional breast cancer treatment. Eur J Pharmacol 625:122\u2013130. https:\/\/doi.org\/10.1016\/j.ejphar.2009.08.045","journal-title":"Eur J Pharmacol"},{"key":"4700_CR12","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.97643","author":"R Chawla","year":"2021","unstructured":"Chawla R, Rani V, Mishra M, Kumar K (2021) Integrated Role of Nanotechnology and Pharmacogenetics in diagnosis and treatment of diseases. Pharmacogenetics IntechOpen. https:\/\/doi.org\/10.5772\/intechopen.97643","journal-title":"Pharmacogenetics IntechOpen"},{"key":"4700_CR13","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jsps.2020.04.007","volume":"28","author":"B Balkhi","year":"2020","unstructured":"Balkhi B, Alqahtani S, Altayyar W et al (2020) Drug utilization and expenditure of anticancer drugs for breast cancer. SPJ 28:669\u2013674. https:\/\/doi.org\/10.1016\/j.jsps.2020.04.007","journal-title":"SPJ"},{"key":"4700_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/157488506775268515","volume":"1","author":"J Zhang","year":"2006","unstructured":"Zhang J, Tian Q, Zhou SF (2006) Clinical pharmacology of Cyclophosphamide and Ifosfamide. Curr Drug ther 1:55\u201384","journal-title":"Curr Drug ther"},{"key":"4700_CR15","doi-asserted-by":"publisher","unstructured":"Huang Q, Feng L, Li H, Zheng L, Qi X, Wang Y (2020) Jian-Pi-Bu-Xue-Formula alleviates Cyclophosphamide-Induced Myelosuppression via Up-Regulating NRF2\/HO1\/NQO1 signaling. Front Pharmacol 1302. https:\/\/doi.org\/10.3389\/fphar.2020.01302","DOI":"10.3389\/fphar.2020.01302"},{"key":"4700_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/00125817-200203000-00003","volume":"4","author":"DW Nebert","year":"2002","unstructured":"Nebert DW, Roe AL, Vandale SE, Bingham E, Oakley GG (2002) NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med 4:62\u201370. https:\/\/doi.org\/10.1097\/00125817-200203000-00003","journal-title":"Genet Med"},{"key":"4700_CR17","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.1007\/s13277-015-3211-y","volume":"36","author":"M Islam","year":"2015","unstructured":"Islam M, Islam MS, Parvin S et al (2015) Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients. Tumour Biol 36:5451\u20135457. https:\/\/doi.org\/10.1007\/s13277-015-3211-y","journal-title":"Tumour Biol"},{"key":"4700_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3390\/antiox8090369","volume":"8","author":"C Glorieux","year":"2019","unstructured":"Glorieux C, Calderon PB (2019) Cancer Cell sensitivity to Redox-Cycling Quinones is influenced by NAD(P)H: Quinone Oxidoreductase 1 polymorphism. Antioxidants 8:369. https:\/\/doi.org\/10.3390\/antiox8090369","journal-title":"Antioxidants"},{"key":"4700_CR19","doi-asserted-by":"publisher","unstructured":"Nagata M, Kimura T, Suzumura T, Kira Y, Nakai T, Umekawa K (2013) C609T polymorphism of NADPH quinone oxidoreductase 1 correlates clinical hematological toxicities in lung cancer patients treated with amrubicin. Clin Med Insights Oncol 31\u201340. https:\/\/doi.org\/10.4137\/CMO.S10839","DOI":"10.4137\/CMO.S10839"},{"key":"4700_CR20","doi-asserted-by":"publisher","first-page":"e1009732","DOI":"10.1371\/journal.pgen.1009732","volume":"17","author":"FS Akhtari","year":"2021","unstructured":"Akhtari FS, Green AJ, Small GW, Havener TM, House JS, Roell KR (2021) High-throughput screening and genome-wide analyses of 44 anticancer drugs in the 1000 genomes cell lines reveals an association of the NQO1 gene with the response of multiple anticancer drugs. PLoS Genet 17:e1009732. https:\/\/doi.org\/10.1371\/journal.pgen.1009732","journal-title":"PLoS Genet"},{"key":"4700_CR21","doi-asserted-by":"publisher","first-page":"659550","DOI":"10.3389\/fmolb.2021.659550","volume":"8","author":"K Shortall","year":"2021","unstructured":"Shortall K, Djeghader A, Magner E, Soulimane T (2021) Insights into Aldehyde dehydrogenase enzymes: a structural perspective. Front Mol Biosci 8:659550. https:\/\/doi.org\/10.3389\/fmolb.2021.659550","journal-title":"Front Mol Biosci"},{"key":"4700_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0009-2797(00)00270-2","volume":"130","author":"AJ Townsend","year":"2001","unstructured":"Townsend AJ, Leone-Kabler S, Haynes RL, Wu Y, Szweda L, Bunting KD (2001) Selective protection by stably transfected human ALDH3A1 (but not human ALDH1A1) against toxicity of aliphatic aldehydes in V79 cells. Chem Biol Interact 130:261\u2013273. https:\/\/doi.org\/10.1016\/S0009-2797(00)00270-2","journal-title":"Chem Biol Interact"},{"key":"4700_CR23","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/modpathol.2013.189","volume":"27","author":"L Yang","year":"2014","unstructured":"Yang L, Ren Y, Yu X et al (2014) ALDH1A1 defines invasive cancer stem-like cells and predicts poor prognosis in patients with esophageal squamous cell carcinoma. Mod Pathol 27:775\u2013783. https:\/\/doi.org\/10.1038\/modpathol.2013.189","journal-title":"Mod Pathol"},{"key":"4700_CR24","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00228-018-2505-6","volume":"74","author":"S Kalra","year":"2018","unstructured":"Kalra S, Kaur RP, Ludhiadch A et al (2018) Association of CYP2C19*2 and ALDH1A1*1\/*2 variants with disease outcome in breast cancer patients: results of a global screening array. Eur J Clin Pharmacol 74:1291\u20131298. https:\/\/doi.org\/10.1007\/s00228-018-2505-6","journal-title":"Eur J Clin Pharmacol"},{"key":"4700_CR25","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1111\/bcp.14031","volume":"85","author":"NA Helsby","year":"2019","unstructured":"Helsby NA, Yong M, van Kan M, de Zoysa JR, Burns KE (2019) The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes. Br J Clin Pharmacol 85:1925\u20131934. https:\/\/doi.org\/10.1111\/bcp.14031","journal-title":"Br J Clin Pharmacol"},{"key":"4700_CR26","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1097\/FPC.0b013e328313aaa4","volume":"18","author":"C Ekhart","year":"2008","unstructured":"Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD (2008) Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genomics 18:1009\u20131015. https:\/\/doi.org\/10.1097\/FPC.0b013e328313aaa4","journal-title":"Pharmacogenet Genomics"},{"key":"4700_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/tpj.2013.32","volume":"14","author":"S Yao","year":"2014","unstructured":"Yao S, Sucheston LE, Zhao H et al (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241\u2013247. https:\/\/doi.org\/10.1038\/tpj.2013.32","journal-title":"Pharmacogenomics J"},{"key":"4700_CR28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur Jour Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur Jour Cancer"},{"key":"4700_CR29","unstructured":"National Institutes of Health (2017) Protocol Development | CTEP. Cancer.gov. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm [Accessed 1 Jan. 2022]"},{"key":"4700_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cca.2012.11.011","volume":"416","author":"MS Islam","year":"2013","unstructured":"Islam MS, Ahmed MU, Sayeed MS et al (2013) Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population. Clin Chim Acta 416:11\u201319. https:\/\/doi.org\/10.1016\/j.cca.2012.11.011","journal-title":"Clin Chim Acta"},{"key":"4700_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jare.2021.02.001","volume":"33","author":"MN Parvin","year":"2021","unstructured":"Parvin MN, Aziz MA, Rabbi SNI et al (2021) Assessment of the link of ABCB1 and NR3C1 gene polymorphisms with the prednisolone resistance in pediatric nephrotic syndrome patients of Bangladesh: a genotype and haplotype approach. J Adv Res 33:141\u2013151. https:\/\/doi.org\/10.1016\/j.jare.2021.02.001","journal-title":"J Adv Res"},{"issue":"5","key":"4700_CR32","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/carcin\/bgg019","volume":"24","author":"J Zhang","year":"2003","unstructured":"Zhang J, Schulz WA, Li Y et al (2003) Association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism with esophageal squamous cell carcinoma in a German caucasian and a northern Chinese population. Carcinogenesis 24(5):905\u2013909. https:\/\/doi.org\/10.1093\/carcin\/bgg019","journal-title":"Carcinogenesis"},{"issue":"12","key":"4700_CR33","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/FPC.0b013e32834b6918","volume":"21","author":"D Jamieson","year":"2011","unstructured":"Jamieson D, Cresti N, Bray J, Sludden J, Griffin MJ, Hawsawi NM, Famie E, Mould EV, Verrill MW, May FE, Boddy AV (2011) Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenet Genomics 21(12):808\u2013819. https:\/\/doi.org\/10.1097\/FPC.0b013e32834b6918","journal-title":"Pharmacogenet Genomics"},{"issue":"7\u20138","key":"4700_CR34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10528-015-9683-z","volume":"53","author":"P Chaturvedi","year":"2015","unstructured":"Chaturvedi P, Tulsyan S, Agarwal G et al (2015) Relationship of MTHFR and NQO1 pharmacogenetics and chemotherapy clinical outcomes in breast Cancer patients. Biochem Genet 53(7\u20138):211\u2013222. https:\/\/doi.org\/10.1007\/s10528-015-9683-z","journal-title":"Biochem Genet"},{"key":"4700_CR35","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3816\/CBC.2007.n.035","volume":"7","author":"T Fojo","year":"2007","unstructured":"Fojo T, Coley HM (2007) The role of Efflux pumps in Drug-resistant metastatic breast Cancer: New insights and Treatment strategies. Clin Breast Cancer 7:749\u2013756. https:\/\/doi.org\/10.3816\/CBC.2007.n.035","journal-title":"Clin Breast Cancer"},{"key":"4700_CR36","doi-asserted-by":"publisher","first-page":"9301","DOI":"10.1038\/srep09301","volume":"5","author":"Z Wang","year":"2015","unstructured":"Wang Z, Liang S, Lian X et al (2015) Identification of proteins responsible for adriamycin resistance in breast cancer cells using proteomics analysis. Sci Rep 5:9301. https:\/\/doi.org\/10.1038\/srep09301","journal-title":"Sci Rep"},{"key":"4700_CR37","doi-asserted-by":"publisher","first-page":"658552","DOI":"10.3389\/fonc.2021.658552","volume":"11","author":"J Cao","year":"2021","unstructured":"Cao J, Zhang M, Wang B, Zhang L, Fang M, Zhou F (2021) Chemoresistance and metastasis in breast Cancer Molecular mechanisms and Novel Clinical Strategies. Front Oncol 11:658552. https:\/\/doi.org\/10.3389\/fonc.2021.658552","journal-title":"Front Oncol"},{"key":"4700_CR38","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1146\/annurev.pharmtox.37.1.269","volume":"37","author":"UA Meyer","year":"1997","unstructured":"Meyer UA, Zanger UM (1997) Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37:269\u2013296. https:\/\/doi.org\/10.1146\/annurev.pharmtox.37.1.269","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"4700_CR39","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/jhg.2009.79","volume":"54","author":"SK Low","year":"2009","unstructured":"Low SK, Kiyotani K, Mushiroda T, Daigo Y, Nakamura Y, Zembutsu H (2009) Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. J Hum Genet 54:564\u2013571. https:\/\/doi.org\/10.1038\/jhg.2009.79","journal-title":"J Hum Genet"},{"key":"4700_CR40","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1182\/blood-2017-01-725705","volume":"129","author":"M Delforge","year":"2017","unstructured":"Delforge M, Ludwig H (2017) How I manage the toxicities of myeloma drugs. Blood 129:2359\u20132367. https:\/\/doi.org\/10.1182\/blood-2017-01-725705","journal-title":"Blood"},{"key":"4700_CR41","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1634\/theoncologist.2019-0699","volume":"25","author":"B Feinberg","year":"2020","unstructured":"Feinberg B, Kish J, Dokubo I, Wojtynek J, Gajra A, Lord K (2020) Comparative effectiveness of Palliative Chemotherapy in metastatic breast Cancer: a real-world evidence analysis. Oncologist 25:319\u2013326. https:\/\/doi.org\/10.1634\/theoncologist.2019-0699","journal-title":"Oncologist"},{"key":"4700_CR42","doi-asserted-by":"publisher","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","volume":"18","author":"WJ Gradishar","year":"2020","unstructured":"Gradishar WJ, Anderson BO, Abraham J et al (2020) Breast Cancer, Version 3.2020, NCCN Clinical Practice guidelines in Oncology. JNCCN 18:452\u2013478. https:\/\/doi.org\/10.6004\/jnccn.2020.0016","journal-title":"JNCCN"},{"key":"4700_CR43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/jco.2005.02.120","volume":"23","author":"M Michael","year":"2005","unstructured":"Michael M, Doherty MM (2005) Tumoral Drug Metabolism: overview and its implications for Cancer Therapy. J Clin Oncol 23:205\u2013229. https:\/\/doi.org\/10.1200\/jco.2005.02.120","journal-title":"J Clin Oncol"},{"key":"4700_CR44","first-page":"2672","volume":"5","author":"RB Diasio","year":"1999","unstructured":"Diasio RB, Johnson MR (1999) Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 5:2672\u20132673","journal-title":"Clin Cancer Res"},{"key":"4700_CR45","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1021\/acsmedchemlett.7b00265","volume":"8","author":"R Dutour","year":"2017","unstructured":"Dutour R, Cort\u00e9s-Ben\u00edtez F, Roy J, Poirier D (2017) Structure-based design and synthesis of New Estrane\u2013pyridine derivatives as cytochrome P450 (CYP) 1B1 inhibitors. ACS Med Chem 8:1159\u20131164. https:\/\/doi.org\/10.1021\/acsmedchemlett.7b00265","journal-title":"ACS Med Chem"},{"key":"4700_CR46","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/03602532.2019.1632886","volume":"51","author":"H Verma","year":"2019","unstructured":"Verma H, Bahia MS, Choudhary S, Singh PK, Silakari O (2019) Drug metabolizing enzymes-associated chemo resistance and strategies to overcome it. Drug Metab Rev 51:196\u2013223. https:\/\/doi.org\/10.1080\/03602532.2019.1632886","journal-title":"Drug Metab Rev"},{"key":"4700_CR47","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s13277-015-3929-6","volume":"37","author":"A Yadav","year":"2016","unstructured":"Yadav A, Gupta A, Rastogi N et al (2016) Association of cancer stem cell markers genetic variants with gallbladder cancer susceptibility, prognosis, and survival. Tumour Biol 37:1835\u20131844. https:\/\/doi.org\/10.1007\/s13277-015-3929-6","journal-title":"Tumour Biol"},{"key":"4700_CR48","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1124\/mol.59.2.263","volume":"59","author":"D Siegel","year":"2001","unstructured":"Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D (2001) Rapid Polyubiquitination and Proteasomal Degradation of a mutant form of NAD(P)H:Quinone Oxidoreductase 1. Mol Pharmacol 59:263\u2013268. https:\/\/doi.org\/10.1124\/mol.59.2.263","journal-title":"Mol Pharmacol"},{"key":"4700_CR49","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/01635581.2018.1460674","volume":"70","author":"U Yadav","year":"2018","unstructured":"Yadav U, Kumar P, Rai V (2018) NQO1 gene C609T polymorphism (dbSNP: rs1800566) and Digestive Tract Cancer risk: a Meta-analysis. Nutr Cancer 70:557\u2013568. https:\/\/doi.org\/10.1080\/01635581.2018.1460674","journal-title":"Nutr Cancer"},{"key":"4700_CR50","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/FPC.0000000000000431","volume":"31","author":"JE Meg\u00edas-Vericat","year":"2021","unstructured":"Meg\u00edas-Vericat JE, Mart\u00ednez-Cuadr\u00f3n D, Herrero MJ et al (2021) Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia. Pharmacogenet Genomics 31:133\u2013139. https:\/\/doi.org\/10.1097\/FPC.0000000000000431","journal-title":"Pharmacogenet Genomics"},{"key":"4700_CR51","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/ng.155","volume":"40","author":"R Fagerholm","year":"2008","unstructured":"Fagerholm R, Hofstetter B, Tommiska J et al (2008) NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 40:844\u2013853. https:\/\/doi.org\/10.1038\/ng.155","journal-title":"Nat Genet"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04700-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04700-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04700-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T15:02:22Z","timestamp":1727535742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04700-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["4700"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04700-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,16]]},"assertion":[{"value":"13 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research protocol was reviewed and approved by the committee for ethical clearance and review, Southeast University, Bangladesh.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}